AstraZeneca (LON:AZN) had its target price trimmed by Jefferies Financial Group from GBX 6,400 ($83.63) to GBX 6,350 ($82.97) in a report issued on Friday morning, Borsen Zeitung reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.
Several other analysts have also recently commented on the company. Deutsche Bank restated a buy rating and set a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a report on Monday, April 8th. Liberum Capital restated a hold rating on shares of AstraZeneca in a report on Friday, March 29th. JPMorgan Chase & Co. set a GBX 7,100 ($92.77) target price on AstraZeneca and gave the stock a buy rating in a report on Thursday, February 14th. Shore Capital restated a buy rating on shares of AstraZeneca in a report on Monday, February 25th. Finally, Bryan, Garnier & Co restated a neutral rating on shares of AstraZeneca in a report on Friday, March 29th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average target price of GBX 6,425.16 ($83.96).
Shares of LON:AZN opened at GBX 6,089 ($79.56) on Friday. AstraZeneca has a fifty-two week low of GBX 5,110 ($66.77) and a fifty-two week high of GBX 6,540 ($85.46). The firm has a market capitalization of $79.87 billion and a price-to-earnings ratio of 32.05. The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Are sell-side analysts objective?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.